Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

January 10, 2028

Conditions

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)

Interventions

DRUG

Equecabtagene Autoleucel Injection

dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.

Trial Locations (1)

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors

collaborator

Nanjing IASO Biotechnology Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER